55,098 Shares in Johnson & Johnson (NYSE:JNJ) Acquired by Zions Bancorporation National Association UT

Zions Bancorporation National Association UT acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 55,098 shares of the company's stock, valued at approximately $9,137,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Highline Wealth Partners LLC grew its stake in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the period. von Borstel & Associates Inc. purchased a new position in Johnson & Johnson during the 1st quarter valued at approximately $49,000. Capital A Wealth Management LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at about $50,000. Harvest Fund Management Co. Ltd purchased a new stake in Johnson & Johnson in the 1st quarter valued at about $52,000. Finally, Accredited Wealth Management LLC purchased a new position in Johnson & Johnson during the 4th quarter valued at about $58,000. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on JNJ. Morgan Stanley raised their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Raymond James Financial lowered their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Finally, Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Stock Up 0.5%

Shares of Johnson & Johnson stock opened at $171.41 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $172.18. The company has a 50-day moving average of $158.89 and a 200 day moving average of $157.27. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market cap of $412.81 billion, a price-to-earnings ratio of 18.33, a PEG ratio of 2.17 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business's revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company earned $2.82 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.